6AF1465C-7A6C-4AAF-AFF2-3065EA5B7D0B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 211.00525624178712
- age_years
- 35
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.565
- G2M_CHECKPOINT+0.551
- MYC_TARGETS_V1+0.485
- MYC_TARGETS_V2+0.453
- DNA_REPAIR+0.437
- NOTCH_SIGNALING+0.391
- UNFOLDED_PROTEIN_RESPONSE+0.389
- HEDGEHOG_SIGNALING+0.378
- ANGIOGENESIS+0.358
- APOPTOSIS+0.344
Top 10 suppressed
- KRAS_SIGNALING_DN-0.319
- BILE_ACID_METABOLISM-0.161
- MYOGENESIS-0.146
- PANCREAS_BETA_CELLS-0.116
- XENOBIOTIC_METABOLISM-0.078
- FATTY_ACID_METABOLISM-0.039
- ESTROGEN_RESPONSE_LATE-0.027
- ESTROGEN_RESPONSE_EARLY+0.019
- ADIPOGENESIS+0.058
- HEME_METABOLISM+0.073
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.940 |
| 2 | SRR934981 | — | — | 0.937 |
| 3 | 68B73B22-487B-43D8-9B68-06AD1022F46D | — | — | 0.932 |
| 4 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.930 |
| 5 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.930 |
| 6 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.929 |
| 7 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.925 |
| 8 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.924 |
| 9 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.923 |
| 10 | 7AA08B08-B1DD-47AB-A0F2-850F6DE95093 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.565 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.551 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.485 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.453 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.437 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.391 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.389 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.378 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.358 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.344 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.343 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.334 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.325 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.309 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.275 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.271 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.256 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.252 | Idelalisib | — uncovered |